0501 GMT - PolyNovo keeps its bulls at Morgans despite the medical-device maker's 2H revenue slowdown. Maintaining a buy rating on the stock, the Australian broker's analysts tell clients in a note that, while sales disappointed, cash generation is strong. They think this indicates the wound-treatment specialist is in a good position to deliver material Ebitda growth in each of its next two fiscal years. Morgans analysts say they remain confident that revenue growth can return above-20% levels in fiscal 2027, pointing out that 15.5% U.S. sales growth in fiscal 2026 was said by management to reflect some seasonality and shifts in insurance reimbursements. Morgans cuts its target price by 5.1% to 1.48 Australian dollars. Shares are down 3.4% at A$0.85.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.